ORIGIN 3 is a Phase 3 clinical trial researching an investigational medication called atacicept in adults with IgAN. The trial will measure the effectiveness of atacicept at improving kidney function by preventing damage caused by the buildup of IgA in the kidneys.
Now enrolling – see if you are eligible.
Learn More